Too much hope in the PRThey simply should have disclosed that they were pausing enrolment due to SAE S and little efficacy.
and that they would continue investigating the results and provide a further update after f consultations with Fda
I would not have disclosed the intent to amend the protocol for lower dosage at more frequent intervals........unless there is a clear scientific basis supported by data ....
Bite the bullet and move on and if by chance they find a viable path forward then provide a positive update
In the meantime FOCuS on increasing sales and surprise the market with a partnership agreement on Nash